Overview

Invicro uniquely combines operational excellence with extensive scientific and medical expertise. Our goal is to drive the advancement of translational cancer research, aid in cancer drug development and develop imaging methods and tools that enable precision medicine. We have experience working with a wide range of therapeutics, including small molecules, peptides, antibodies, multi-specific proteins, CAR-T cells, and many more. Preclinically and clinically, Invicro offers a wide variety of oncology biomarker solutions, including:

  • Central imaging core lab for Phase 0-IV clinical studies
  • Preclinical/Clinical novel molecular imaging tracers
  • In vitro, in vivo, and ex vivo techniques in rodents through NHPs
  • Autoradiography, histology and quantitative immunohistochemistry
  • Qualitative and quantitative image analytics
Capabilities
Rodent Models

We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:

  • Syngeneic models
  • Human xenograft tumors in immunocompromised mice
  • Humanized mouse models
  • GEMM mouse model

We also work with larger species including canine, porcine, and non-human primates (NHP).

Clinical Core Lab

Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:

  • Segmentation
  • Image co-registration
  • Radiation dosimetry
  • Mechanistic pharmacokinetic modeling including PBPK modeling
  • Tracer kinetic modeling
  • Radiomics
  • Imaged-based machine learning
  • Full service independent blind reads or collect and hold capabilities
  • Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC

 

Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.

  • Focal adhesion kinase inhibitor GSK2256098 (Neuro Oncol. 2018 May 17)
  • Lapatinib (EJNMMI Res. 2015 Apr 30;5:30)
Modalities
in vivo
  • PET
  • SPECT
  • CT
  • MR
  • US
  • Bioluminescence
  • Fluorescence Molecular Tomography (FMT)
ex vivo
  • Cryo-fluorescence tomography (CFT)
  • ex vivo fluorescence reflectance imaging
  • Autoradiography & micro-autoradiography
  • Histology, immunohistochemistry, and quantitative immunohistochemistry
  • Gamma counting
  • Flow cytometry
  • Clinical chemistry
  • CBC analysis
  • Urinalysis
in vitro & chemistry
  • Tissue homogenate binding
  • Cell culture
  • Cell binding and competition
  • Internalization
  • ELISA
  • Western blots
  • Targeted radiotherapeutics